Loading news...
Assetmark Inc. boosted its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 5.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 213,793 shares of the medical research company's stock after acquiring an additional 10,886 shares during the quarter. Assetmark Inc.'s
Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold
/PRNewswire/ -- Amgen (NASDAQ: AMGN) gab heute bekannt, dass die Europäische Kommission (EC) UPLIZNA (Inebilizumab) als Zusatzbehandlung zur Standardtherapie
THOUSAND OAKS, Calif., Feb. 13, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m.
/PRNewswire/ -- Spoločnosť Amgen (NASDAQ: AMGN) dnes oznámila, že Európska komisia (EK) schválila liek UPLIZNA (inebilizumab) ako doplnkovú liečbu k
/PRNewswire/ - Společnost Amgen (NASDAQ: AMGN) dnes oznámila, že Evropská komise (EK) schválila přípravek UPLIZNA (inebilizumab) jako přídavnou léčbu ke
Stock News Tech slump hits indexes: A broad risk-off move saw Apple (AAPL) and Cisco (CSCO) lead declines, while Applied Materials (AMAT) rallied on upbeat AI t
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
/PRNewswire/ -- Amgen (NASDAQ: AMGN) a annoncé aujourd'hui que la Commission européenne (CE) avait approuvé UPLIZNA (inebilizumab) comme traitement d'appoint
/PRNewswire/ -- Amgen (NASDAQ: AMGN) anunció hoy que la Comisión Europea (CE) ha aprobado UPLIZNA (inebilizumab) como tratamiento complementario al tratamiento
Eubel Brady and Suttman Asset Management Inc. purchased a new position in shares of Amgen Inc. (NASDAQ: AMGN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,416 shares of the medical research company's stock, valued at approximately $1,246,000. Other hedge funds and
One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Advisors Asset Management Inc. lowered its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 1.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 109,990 shares of the medical research company's stock after selling 2,136 shares during
Wealthfront Advisers LLC boosted its position in Amgen Inc. (NASDAQ: AMGN) by 22.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,233 shares of the medical research company's stock after purchasing an additional 12,857 shares during the
Allegheny Financial Group cut its position in shares of Amgen Inc. (NASDAQ: AMGN) by 76.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,899 shares of the medical research company's stock after selling 6,112 shares during the period. Allegheny
Alps Advisors Inc. raised its holdings in Amgen Inc. (NASDAQ: AMGN) by 63.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,759 shares of the medical research company's stock after buying an additional 7,254 shares during the period. Alps Advisors Inc.'s holdings
Amgen Inc. (NASDAQ: AMGN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and one has
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.